What SEC filings does Immunocore Holdings plc submit to the SEC?

Immunocore Holdings plc (IMCR) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about IMCR?

A Form 4 for IMCR discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Immunocore Holdings plc?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for IMCR?

The 10-K is Immunocore Holdings plc's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all IMCR SEC filings directly on EDGAR?

You can view all historical Immunocore Holdings plc filings on the SEC EDGAR company page for IMCR. Each filing card on this page links directly to the original SEC document.

How often does Immunocore Holdings plc file with the SEC?

Immunocore Holdings plc files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling IMCR shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

IMCR SEC Filing News — Immunocore Holdings plc

Latest SEC filings for Immunocore Holdings plc (IMCR) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-14.

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuv…

Sector: Healthcare Industry: Biotechnology Market Cap: $1.5B CIK: 1671927

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for IMCR currently lean bearish. Of the 20 filing records displayed, 1 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

IMCR Filing Activity Snapshot 2026-02-19 — 2026-09-14

Insider Transactions (Form 4)

0 buys vs 1 sell

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$2.04M

David Berman · 2026-05-22

69,271 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for Immunocore Holdings plc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 7 compensation award and 1 open-market sale. 1 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×1: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Compensation award Tax / Compensation Filing 2026-05-28

IMCR insider Form 4 filed for equity award, exercise, or tax withholding

Ratcliffe Peter John (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share Option (Right to Buy)	27,492	—	—

Filing: Form 4 (Insider Transaction) Insider: Ratcliffe Peter John (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-28

IMCR insider Form 4 filed for equity award, exercise, or tax withholding

Peterson Kristine (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share Option (Right to Buy)	27,492	—	—

Filing: Form 4 (Insider Transaction) Insider: Peterson Kristine (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-28

IMCR insider Form 4 filed for equity award, exercise, or tax withholding

Pao William (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share Option (Right to Buy)	27,492	—	—

Filing: Form 4 (Insider Transaction) Insider: Pao William (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-28

IMCR insider Form 4 filed for equity award, exercise, or tax withholding

Kaul Siddharth (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share Option (Right to Buy)	27,492	—	—

Filing: Form 4 (Insider Transaction) Insider: Kaul Siddharth (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-28

IMCR insider Form 4 filed for equity award, exercise, or tax withholding

Herbst Roy Steven (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share Option (Right to Buy)	27,492	—	—

Filing: Form 4 (Insider Transaction) Insider: Herbst Roy Steven (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-05-28

IMCR insider Form 4 filed for equity award, exercise, or tax withholding

Bell John Irving (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share Option (Right to Buy)	27,492	—	—

Filing: Form 4 (Insider Transaction) Insider: Bell John Irving (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-02-19

IMCR insider Form 4 filed for equity award, exercise, or tax withholding

Coy Travis Alan (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Restricted Share Units	33,353	—	—
`A`	Compensation award derivative · Employee Share Option (Right to Buy)	95,637	—	—

Filing: Form 4 (Insider Transaction) Insider: Coy Travis Alan (Chief Financial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-02-19

IMCR insider Jallal Bahija (Director, CHIEF EXECUTIVE OFFICER) sold 11,474 shares (~$371.2K)

Jallal Bahija, listed as Director, CHIEF EXECUTIVE OFFICER at Immunocore Holdings plc, reported an open-market sale of 11,474 IMCR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	23,817	—	—
`S`	Open-market sale	11,474	$32.35	$371.2K
`M`	Option exercise derivative · Restricted Share Units	23,817	—	—
`A`	Compensation award derivative · Restricted Share Units	88,573	—	—
`A`	Compensation award derivative · Employee Share Option (Right to Buy)	395,066	—	—

Filing: Form 4 (Insider Transaction) Insider: Jallal Bahija (Director, CHIEF EXECUTIVE OFFICER) Shares: 11,474 Est. Value: $371.2K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 4 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Immunocore Holdings plc has 4 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-05-22

IMCR Form 144 filed for proposed insider sale by David Berman (69,271 shares) ~$2.04M

David Berman filed a Form 144 with the SEC indicating intent to sell IMCR (Immunocore Holdings plc) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: David Berman Shares: 69,271 Est. Value: $2.04M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-05-21

IMCR Form 144 filed for proposed insider sale by David Berman (65,000 shares) ~$1.89M

Filing: Form 144 (Proposed Sale Notice) Insider: David Berman Shares: 65,000 Est. Value: $1.89M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-04-08

IMCR Form 144 filed for proposed insider sale by David Berman (25,000 shares) ~$796.2K

Filing: Form 144 (Proposed Sale Notice) Insider: David Berman Shares: 25,000 Est. Value: $796.2K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-03-11

IMCR Form 144 filed for proposed insider sale by David Berman (11,832 shares) ~$385.3K

Filing: Form 144 (Proposed Sale Notice) Insider: David Berman Shares: 11,832 Est. Value: $385.3K

View on SEC EDGAR → Open Filing Document →

Material Events 5 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 5 in this period for Immunocore Holdings plc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-14

IMCR filed 8-K — material company event

Immunocore Holdings plc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-06

IMCR filed 8-K — material company event

Immunocore Holdings plc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-05-27

IMCR filed 8-K — material company event

Immunocore Holdings plc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-05-06

IMCR filed 8-K — material company event

Immunocore Holdings plc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-02-25

IMCR filed 8-K — material company event

Immunocore Holdings plc filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 3 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 2 quarterly reports (10-Q) for Immunocore Holdings plc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

IMCR filed Quarterly Report (10-Q)

Immunocore Holdings plc filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-05-06

IMCR filed Quarterly Report (10-Q)

Immunocore Holdings plc filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-K Annual Report 2026-02-25

IMCR filed Annual Report (10-K)

Immunocore Holdings plc filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)

View on SEC EDGAR → Open Filing Document →

How we classify Immunocore Holdings plc's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on IMCR. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — IMCR SEC Filings

More Tools for IMCR

IMCR Full Stock Analysis IMCR Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper IMCR analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the IMCR stock analysis page.

IMCR Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer